Assessing the effectiveness of RIG-I and TLR-7/8 agonists as adjuvants, when co-administered with a licensed quadrivalent inactivated influenza vaccine

For each animal, 1.5mg HA equivalent of QIV was mixed with 1mg SDI-RNA (with 40ug nanogel; 1:40 ratio) or 100 mg IMDQ-PEG-Chol (equivalent to 10 mg core IMDQ) or both and vortexed for 30 seconds. Unadjuvanted or adjuvanted QIV was administered intramuscularly in a total of 100ml per mouse, divided equally over both hind legs. The control group were administered with equal volume of PBS instead of vaccine or vaccine/ adjuvant mixture, divided over both hind legs. All animals received QIV+IMDQ-PEG-Chol as booster, irrespective of the prime vaccination.